HSS Announces New Chief of Endocrinology Division and Metabolic Bone Service

Hospital for Special Surgery (HSS), the world's leading academic medical center specialized in musculoskeletal health, today announced the appointment of Matthew T. Drake, MD, PhD, chief of the Division of Endocrinology and director of the Metabolic Bone Service. Effective January 1, 2025. Dr. Drake will assume these duties from Emily Stein, MD, MS, who has very capably served as Interim Director since March 2023.

Dr. Drake has been a consultant in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic in Rochester, Minnesota since 2007. He assumed a dual role as a consultant in Mayo Clinic’s Division of Hematology in 2017. He has been an Associate Professor of Medicine at the Mayo Clinic College of Medicine and Science since 2015.

Dr. Drake will ensure the continued excellence of the clinical, educational and investigative programs in the Division of Endocrinology and the Metabolic Bone Service. He will work with HSS physicians and staff to optimize quality, the patient experience and outcomes. His role will include collaboration with internists and orthopedic surgeons at HSS, particularly those focused on joint replacement, sports medicine and spine, to identify and address risk factors related to bone health that could affect surgical outcomes.

“Dr. Drake is a world-renowned endocrinologist with clinical and research expertise on age related bone loss, and we enthusiastically welcome him to HSS,” said S. Louis Bridges, Jr., MD, PhD, physician-in-chief and chair of the Department of Medicine at HSS. “His impressive background and considerable experience are vital assets that will enable us to maintain our role as a leader in the diagnosis, treatment and research in endocrine and metabolic bone diseases.”

“With its outstanding reputation for providing the highest standards of care, passion for excellence and innovation, and strong commitment to improving the lives of patients everywhere, it is an honor and a privilege to join HSS,” said Dr. Drake. “I look forward to working closely with the clinical and research staff and collaborating with a highly motivated team of specialized faculty to achieve our best musculoskeletal health outcomes.”

The recipient of numerous research grants from the National Institutes of Health, Dr. Drake will play a key role in the internationally recognized research programs at HSS, collaborating with leaders of the HSS Research Institute, the Department of Orthopedics and the Division of Rheumatology, to define priorities for investigation.

Dr. Drake’s own research has focused on the underlying mechanisms and skeletal changes related to age-related bone loss. He has also sought to better understand how cancer affects bone health. Dr. Drake believes that unraveling the mysteries of how normal aging or the presence of malignancies leads to the softening or destruction of bone mass could ultimately lead to new or improved methods to prevent and treat bone loss.

Dr. Drake’s dedication to his field includes a long list of professional activities. He has served as an independent content reviewer on the Task Force on Cell-Based Therapies for the American Society for Bone and Mineral Research (ASMBR); as a member of the Task Force on Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment for the ASBMR; and on the scientific advisory boards of the Rare Bone Disease Alliance, Fibrous Dysplasia Foundation, and the Soft Bones Foundation.

His research has been featured in 125 peer-reviewed articles, and he has written 11 book chapters on topics that include the pathogenesis of osteoporosis, myeloma bone disease, and disorders of calcium and bone metabolism.

Dr. Drake graduated Magna Cum Laude from Harvard College, where he received an AB degree in Biology. He attended Washington University earning his MD degree in addition to a PhD in Molecular and Cell Biology. He went on to an Internal Medicine/Endocrinology residency at Duke University Medical Center, where he also completed a clinical research fellowship. His academic accomplishments include a second clinical research fellowship in Endocrinology at the Mayo Clinic College of Medicine.

“The advancement of patient care practices at HSS is demonstrated through our commitment to recruiting outstanding physician leaders in our clinical specialties,” said Douglas E. Padgett, MD, surgeon-in-chief and medical director at HSS. “Drs. Drake’s and Stein’s dedication and expertise in the field of endocrinology demonstrates our relentless focus on high-quality and high-value healthcare for our patients.”

About HSS

HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 15th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2024-2025), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2024-2025). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fifth consecutive year (2025). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121974359/en/